NCT05926414: To Evaluate the Efficacy and Safety of Envlo Tablet or Envlomet SR Tablet in Patients With Type II Diabetes Mellitus |
|
|
| Recruiting | N/A | 15000 | RoW | Enavogliflozin, Envlo Tablet, Envlomet SR Tablet | Daewoong Pharmaceutical Co. LTD. | Diabetes Mellitus, Type 2 | 12/24 | 06/25 | | |
